Sionna Therapeutics Common Stock Performance
| SION Stock | 34.57 0.48 1.41% |
The entity has a beta of 0.0657, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Sionna Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Sionna Therapeutics is expected to be smaller as well. At this point, Sionna Therapeutics has a negative expected return of -0.13%. Please make sure to validate Sionna Therapeutics' treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Sionna Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Sionna Therapeutics Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's basic indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors. ...more
Actual Historical Performance (%)
One Day Return 1.41 | Five Day Return (7.19) | Year To Date Return (11.83) | Ten Year Return 38.28 | All Time Return 38.28 |
1 | Disposition of 10250 shares by Jennifer Fitzpatrick of Sionna Therapeutics, at 40.52 subject to Rule 16b-3 | 12/05/2025 |
2 | Disposition of 801 shares by Ra Capital Management, L.p. of Sionna Therapeutics, at .89 subject to Rule 16b-3 | 12/12/2025 |
3 | Disposition of 900 shares by Thompson Peter A. of Sionna Therapeutics at 44.5 subject to Rule 16b-3 | 12/17/2025 |
4 | Disposition of 100 shares by Thompson Peter A. of Sionna Therapeutics at 44.49 subject to Rule 16b-3 | 12/18/2025 |
5 | Disposition of 875 shares by Thompson Peter A. of Sionna Therapeutics at 44.49 subject to Rule 16b-3 | 12/19/2025 |
6 | Disposition of 33356 shares by Thompson Peter A. of Sionna Therapeutics at 44.55 subject to Rule 16b-3 | 12/24/2025 |
7 | Insider Selling Sionna Therapeutics Director Sells 33,356 Shares of Stock | 12/30/2025 |
8 | Acquisition by Ridloff Elena of 165440 shares of Sionna Therapeutics at .21 subject to Rule 16b-3 | 01/02/2026 |
9 | Assessing Sionna Therapeutics Valuation After A Sharp Share Price Move And Elevated Price To Book Ratio | 01/08/2026 |
10 | Sionna Therapeutics Chief Legal Officer Caps Off Strong 2025 with Sale of Over 10,000 Shares - The Motley Fool | 01/12/2026 |
11 | Disposition of 250000 shares by Tpg Gp A, Llc of Sionna Therapeutics at 40.0 subject to Rule 16b-3 | 01/22/2026 |
12 | Disposition of 1890 shares by Orbimed Advisors Llc of Sionna Therapeutics at 44.57 subject to Rule 16b-3 | 02/02/2026 |
13 | Disposition of 29063 shares by Orbimed Advisors Llc of Sionna Therapeutics at 44.58 subject to Rule 16b-3 | 02/03/2026 |
14 | Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook Biotech Summit 2026 | 02/04/2026 |
15 | Sionna Therapeutics to Participate in Upcoming March 2026 Investor Conferences | 02/23/2026 |
| Begin Period Cash Flow | 38.8 M | |
| Total Cashflows From Investing Activities | -118.7 M |
Sionna Therapeutics Relative Risk vs. Return Landscape
If you would invest 4,029 in Sionna Therapeutics Common on December 5, 2025 and sell it today you would lose (572.00) from holding Sionna Therapeutics Common or give up 14.2% of portfolio value over 90 days. Sionna Therapeutics Common is currently does not generate positive expected returns and assumes 4.9159% risk (volatility on return distribution) over the 90 days horizon. In different words, 44% of stocks are less volatile than Sionna, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Sionna Therapeutics Target Price Odds to finish over Current Price
The tendency of Sionna Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 34.57 | 90 days | 34.57 | roughly 97.0 |
Based on a normal probability distribution, the odds of Sionna Therapeutics to move above the current price in 90 days from now is roughly 97.0 (This Sionna Therapeutics Common probability density function shows the probability of Sionna Stock to fall within a particular range of prices over 90 days) .
Sionna Therapeutics Price Density |
| Price |
Predictive Modules for Sionna Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Sionna Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sionna Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Sionna Therapeutics is not an exception. The market had few large corrections towards the Sionna Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Sionna Therapeutics Common, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Sionna Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.25 | |
β | Beta against Dow Jones | 0.07 | |
σ | Overall volatility | 2.90 | |
Ir | Information ratio | -0.06 |
Sionna Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Sionna Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Sionna Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Sionna Therapeutics generated a negative expected return over the last 90 days | |
| Sionna Therapeutics has high historical volatility and very poor performance | |
| Sionna Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (75.27 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Sionna Therapeutics generates negative cash flow from operations | |
| Sionna Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Analysts Bullish on Vera Therapeutics Amid New Commercial Chief Appointment |
Sionna Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Sionna Stock often depends not only on the future outlook of the current and potential Sionna Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Sionna Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 40 M | |
| Cash And Short Term Investments | 235.9 M |
Sionna Therapeutics Fundamentals Growth
Sionna Stock prices reflect investors' perceptions of the future prospects and financial health of Sionna Therapeutics, and Sionna Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sionna Stock performance.
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.22 | ||||
| Current Valuation | 1.27 B | ||||
| Shares Outstanding | 44.63 M | ||||
| Price To Book | 4.69 X | ||||
| EBITDA | (88.98 M) | ||||
| Net Income | (75.27 M) | ||||
| Total Debt | 8.68 M | ||||
| Book Value Per Share | 6.86 X | ||||
| Cash Flow From Operations | (66.3 M) | ||||
| Earnings Per Share | (1.80) X | ||||
| Market Capitalization | 1.52 B | ||||
| Total Asset | 325.95 M | ||||
| Retained Earnings | (256.35 M) | ||||
| Working Capital | 140.57 M | ||||
About Sionna Therapeutics Performance
By examining Sionna Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Sionna Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Sionna Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.23) | (0.24) | |
| Return On Capital Employed | (0.28) | (0.30) | |
| Return On Assets | (0.23) | (0.24) | |
| Return On Equity | (0.25) | (0.23) |
Things to note about Sionna Therapeutics performance evaluation
Checking the ongoing alerts about Sionna Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Sionna Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Sionna Therapeutics generated a negative expected return over the last 90 days | |
| Sionna Therapeutics has high historical volatility and very poor performance | |
| Sionna Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (75.27 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Sionna Therapeutics generates negative cash flow from operations | |
| Sionna Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Analysts Bullish on Vera Therapeutics Amid New Commercial Chief Appointment |
- Analyzing Sionna Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sionna Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Sionna Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Sionna Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sionna Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Sionna Therapeutics' stock. These opinions can provide insight into Sionna Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sionna Therapeutics Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Will Biotechnology sector continue expanding? Could Sionna diversify its offerings? Factors like these will boost the valuation of Sionna Therapeutics. If investors know Sionna will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Sionna Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Sionna Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Sionna Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Sionna Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Sionna Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sionna Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Sionna Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.